FlightPath Biosciences shares Phase I findings and outlines next steps in Lyme disease treatment development.
FlightPath Biosciences announced on May 5 that it will pause development of FP100 following findings from its Phase 1 clinical trial. Flightpath CEO Matt Tindall shared that, “FP100 showed limited oral bioavailability in humans, meaning too little of the drug reached the bloodstream and tissues at levels needed for robust, reliable clinical benefit.” The company is now focusing on another Lyme disease treatment candidate, FP530, which it plans to evaluate in a Phase 1 clinical study later this year.
FP100, a drug candidate derived from the antibiotic hygromycin A, emerged from research by Dr. Kim Lewis and his team at Northeastern University with support from Global Lyme Alliance. His team found that hygromycin A targeted Lyme disease bacteria while sparing healthy gut bacteria, unlike the broad-spectrum antibiotics used to treat Lyme disease. FlightPath Biosciences later licensed hygromycin A, developing it into the FP100 drug candidate and launching a Phase 1 clinical trial in 2024.
While disappointing, setbacks are a common part of drug development. Early laboratory findings do not always translate into successful human outcomes, and clinical trials are designed to evaluate both safety and effectiveness before treatments move forward.
FlightPath aims to assess the safety and efficacy of their new candidate, FP530, in a Phase I clinical study later this year. The company has expressed confidence in its continued development efforts and remains focused on advancing potential therapies for patients with Lyme disease.
Read the full message from the Flightpath CEO here.
Financial Disclosure: Global Lyme Alliance is an investor in Flightpath Biosciences
***
-3.jpg)
-1.jpg)
